Search results
Results from the WOW.Com Content Network
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]
Combined hyperlipidemia (or -aemia) is a commonly occurring form of hypercholesterolemia (elevated cholesterol levels) characterised by increased LDL and triglyceride concentrations, often accompanied by decreased HDL. [1]: 534 On lipoprotein electrophoresis (a test now rarely performed) it shows as a hyperlipoproteinemia type IIB. It is the ...
Mixed hyperlipidemia, in combination with fenofibrate; Homozygous familial hypercholesterolemia, in combination with specific statins; Homozygous sitosterolemia; A 2018 review found that ezetimibe used as sole treatment slightly lowered plasma levels of lipoprotein(a), but the effect was not large enough to be important. [22]
FDA Approves Merck's LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol LIPTRUZET Approved for Patients with Primary or Mixed Hyperlipidemia ...
Dyslipidemia is when the lipids in your blood are too high or too low. Estimates suggest that 53 percent of adults in the U.S. have lipid abnormalities.. Lipids are a type of fat that make up the ...
Treatment of the underlying condition, when possible, or discontinuation of the offending drugs usually leads to an improvement in the hyperlipidemia. Another acquired cause of hyperlipidemia, although not always included in this category, is postprandial hyperlipidemia, a normal increase following ingestion of food. [32] [34]
UK Drug Information: Routes of ... is a combination medication used for the treatment of ... for the treatment of high-risk patients with mixed hyperlipidemia".
It is a combination of ezetimibe (known as Zetia in the United States) and the statin drug simvastatin (known as Zocor in the US). Ezetimibe reduces blood cholesterol by acting at the brush border of the small intestine and inhibiting the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.